How does the 2018 pipeline compare to 2017’s? In Vivo’s 2018 pipeline infographic examines pipelines by therapeutic area, company and phase. Find out which therapeutic areas are growing, which are shrinking, and which pharma companies have the most robust portfolios.
Author: Ian Lloyd
Published: 28 May 2018
Number of pages:2
How does the 2018 pipeline compare to 2017’s? Cancer remained the top therapy group in 2018, with a 7.6 percent increase in the number of therapeutic candidates–almost three times the growth of pipeline overall. That’s one key takeaway from In Vivo’s 2018 pipeline infographic, which examines the active drug pipeline by therapeutic area, company and phase. In terms of companies, Novartis topped the list for a second year running with 223 drugs in its pipeline, despite the fact it dropped by 28 drugs. Find out which of the top 10 pharmaceutical companies, by size of pipeline, increased their portfolio sizes and how the overall pipeline breaks down by phases.
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726